Hospitals in states that expanded Medicaid are reaping financial benefits in excess of original estimates, a new report found.» Read More
If Democrats pull ahead in the race for the White House the team at Goldman has a trade for you.
As the push for universal health care in the U.S. heats up on Capitol Hill, market experts say generic drug stocks and pharmaceutical distributors should perform well, while the hit to big pharma may not be as bad as some anticipate.
Mergers and acquisitions activity was brisk on Monday, giving stocks a lift as M&A deals spanned several industries, including energy, and added to optimism about the prospects for growth in both corporate profits and the U.S. economy.
Stocks closed solidly higher as investors took encouragement from more than $10 billion of announced acquisitions. "We think the one-day drop of a week or so ago was way overdone," Bob Turner, chief investment officer at Turner Investment Partners, told CNBC. "The trend that's been in place over the last several years of an upward bias to the market is still in place."
The deal, subject to Triad shareholder approval, tops a $4.7 billion agreement announced six weeks ago for Triad to be purchased by CCMP Capital Advisors and Goldman Sachs Capital Partners, the private equity arm of Goldman Sachs Group.
Merger madness is gripping Wall Street this morning and stocks, so far, are ready to sprint higher at the open. European markets are trading higher, and Asian stocks rose overnight, with a weaker yen helping lift Japan's Nikkei more than 1.6%.
Triad Hospitals has accepted a takeover bid from affiliates of CCMP Capital Advisors and GS Capital Partners in a deal worth about $4.7 billion, the company said on Monday